Interferon α increases metalloproteinase-13 gene expression through a polyomavirus enhancer activator 3-dependent pathway in hepatic stellate cells

Journal of Hepatology

Volumn 50, Issue 1, 2009, Pages 128-139

  Díaz Sanjuán, Teresa ^a   García Ruiz, Inmaculada ^a   Rodríguez Juan, Cristina ^a   Muñoz Yagüe, Teresa ^a   Solís Muñoz, Pablo ^a   Solís Herruzo, José A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

AP 1; Collagen; Fibrosis; Hepatic stellate cells; Interferon; Metalloproteinase 13; PEA3

Indexed keywords

ALPHA INTERFERON; COLLAGENASE 3; JANUS KINASE 1; SERINE; STAT1 PROTEIN; TRANSCRIPTION FACTOR PEA3; TYROSINE;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; IMMUNOPRECIPITATION; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; GENE EXPRESSION; HEPATIC STELLATE CELLS; INTERFERON-ALPHA; JANUS KINASE 1; MATRIX METALLOPROTEINASE 13; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SERINE; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 56949093946     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.07.034     Document Type: Article

References (43)

1. Arthur M.J.P. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279 (2000) G245-G249
2. Desmet V.J., and Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40 (2004) 860-867
3. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Int Med 132 (2000) 517-524
4. Fort J., Pilette C., Veal N., Oberti F., Gallois Y., Douay O., et al. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats. J Hepatol 29 (1998) 263-270
5. Souza M.M., Paraná R., Trepo C., Barbosa Jr. A.A., Oliveira I., and Andrade Z.A. Effect of interferon-α on experimental septal fibrosis of the liver - study with a new model. Mem Inst Oswaldo Cruz 96 (2001) 343-348
6. Inagaki Y., Nemoto T., Kushida M., Sheng Y., Higashi K., Ikeda K., et al. Interferon alpha down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice. Hepatology 38 (2003) 890-899
7. Mitsuda A., Suou T., Ikuta Y., and Kawasaki H. Changes in serum tissue inhibitor of matrix metalloproteinase-1 after interferon alpha treatment in chronic hepatitis C. J Hepatol 32 (2000) 666-672
8. Rippe R.A., Almounajed G., and Brenner D.A. Sp1 binding activity in activated Ito cells. Hepatology 22 (1995) 241-251
9. Garci{dotless}́a-Ruiz I., De La Torre M., Di{dotless}́az T., Esteban E., Fernández I., Muñoz-Yagüe T., et al. Sp1 and Sp3 transcription factors mediate malondialdehyde-Induced collagen α1(I) gene expression in cultured hepatic stellate cells. J Biol Chem 277 (2002) 30551-30558
10. Soli{dotless}́s-Herruzo J.A., Rippe R.A., Schrum L.W., de La Torre P., Garci{dotless}́a I., Jeffrey J.J., et al. Interleukin-6 increases rat metalloproteinese-13 gene expression through stimulation of activator protein 1 transcription factor in cultured fibroblasts. J Biol Chem 274 (1999) 30919-30926
11. Lang A., Schrum L., Schoonhoven R., Tuvia S., Soli{dotless}́s-Herruzo J.A., Tsukamoto H., et al. Expression of the small heat shock protein αb-crystallin is induced after hepatic stellate cells activation. Am J Physiol 279 (2000) G1333-G1342
12. Hall C.V., Jacob P.E., Ringold G.M., and Lee F. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells. J Mol Appl Genet 2 (1983) 101-109
13. Ho S.N., Hunt H.D., Horton R.M., Pullen J.K., and Pease L.R. Site-directed mutagenesis. Gene 77 (1989) 51-59
14. -ΔΔCT method. Methods 25 (2001) 402-408
15. Launoit Y., Baert J.-L., Chotteau-Lelievre A., Monte D., Coutte L., Mauen S., et al. The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochem Biophy Acta 1766 (2006) 79-87
16. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem 270 (1995) 20801-20807
17. Cuenda A., Rouse J., Doza Y.N., Meier R., Cohen P., Gallagher T.F., et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364 (1995) 229-233
18. Emonard H., and Grimaud J.A. Matrix metalloproteinases. A review. Cel Mol Biol 36 (1990) 131-153
19. Iredale J.P., Murphy G., Hembry R.M., Friedman S.L., and Arthur M.J. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinase I. Implications for regulation of matrix degradation in liver. J Clin Invest 90 (1992) 282-287
20. Ninomiya T., Yoon S., Nagano H., Kumon Y., Seo Y., Kasuga M., et al. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenic effect of interferon-alfa in chronic hepatitis C patients. Intervirol 44 (2001) 227-231
21. Arai M., Niioka M., Maruyama K., Wada N., Fujimoto N., Nomiyama T., et al. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Dig Dis Sci 41 (1996) 995-1000
22. Pendás A.M., Balbin M., Llano E., Jiménez M.G., and López-Oti{dotless}́n C. Structural analysis and promoter characterization of the human collagenase-3 gene (MMP13). Genomics 40 (1997) 222-233
23. Graves B.J., and Petersen J.M. Specificity within the ets family of transcription factors. Adv Cancer Res 75 (1998) 1-55
24. Higashino F., Yoshida K., Noumi T., Seiki M., and Fujinaga K. Ets-related protein E1A-F can activate three different matrix metalloproteinase gene promoters. Oncogene 10 (1995) 1461-1463
25. Selvamurugan N., Chou W.Y., Pearman A.T., Pulumati M.R., and Partridge N.C. Parathyroid hormone regulates the rat collagenase-3 promoter in osteoblastic cells through the cooperative interaction of the activator protein-1 site and the runt domainbinding sequence. J Biol Chem 273 (1998) 10647-10657
26. Donaldson L.W., Petersen J.M., Graves B.J., and McIntosh L.P. Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. EMBO J 15 (1996) 125-134
27. Yang S.H., Shore P., Willingham N., Lakey J.H., and Sharrocks A.D. The mechanism of phosphorylation-inducible activation of the ETS-domain transcription factor Elk-1. EMBO J 18 (1999) 5666-5674
28. Gille H., Kortenjann M., Thomae O., Moomaw C., Slaughter C., Cobb M.H., et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 14 (1995) 951-962
29. Greenall A., Willingham N., Cheung E., Boam D.S., and Sharrocks A.D. DNA binding by the ETS-domain transcription factor PEA3 is regulated by intramolecular and intermolecular protein-protein interaction. J Biol Chem 276 (2001) 16207-16215
30. Firlej V., Bocquet B., Desbiens X., de Launoit Y., and Chotteau-Lelièvre A. Pea3 transcription factor cooperates with USF-1 in regulation of the murine bax transcrition factor without binding to an Ets-binding site. J Biol Chem 280 (2005) 887-898
31. Goel A., and Janknecht R. Acetylation-mediated transcriptional activation of the ETS protein ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol 23 (2003) 6243-6254
32. Su Z.-Z., Shi Y., and Fisher P.B. Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogene phenotype in transformed rat embryo cells. Oncogene 19 (2000) 3411-3421
33. Liu Y., Borchert G.L., and Phang J.M. Polyoma enhancer activator 3, an ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 279 (2004) 18694-18700
34. Aittomaki S., Pesu M., Groner B., Jänne O.A., Palvimo J.J., and Silvennoinen O. Cooperation among Stat1, glucocorticoid receptor, and PU.1 in transcriptional activation of the high-affinity Fc gamma receptor I in monocytes. J Immunol 164 (2000) 5689-5697
35. Tavagli J., Letourneur M., Bertoglio J., and Pierre J. Stat6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in keratinocytes. J Biol Chem 279 (2004) 35183-35192
36. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharm Ther 98 (2003) 129-142
37. O'Hagan R.C., Tozen R.G., Symons M., McCormick F., and Hassell J.A. The activity of the transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 13 (1996) 1323-1333
38. Perez A., Barco R., Fernandez I., Price-Schiavi S.A., and Carraway K.L. PEA3 transactivates the Muc4/Sialomucin complex promoter in mammary epithelial and tumor cells. J Biol Chem 278 (2003) 36942-36952
39. Pestka S., Krause C.D., and Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202 (2004) 8-32
40. Aaronson D.S., and Horvath C.M. A road map for those who don't know JAK-STAT. Science 296 (2002) 1653-1655
41. Li Y., Srivastava K.K., and Platanias L.C. Mechanisms of type I interferon signalling in normal and malignant cells. Arch Immunol Ther Exp 52 (2004) 156-163
42. David M., Petricoin III E., Benjamin C., Pine R., Weber M.J., and Larner A.C. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon-beta-stimulated gene expression through Stat proteins. Science 269 (1995) 1721-1723
43. Kaur S., Uddin S., and Platanias L.C. The PI3' kinase pathway in interferon signaling. J Interferon Cyt Res 25 (2005) 780-787